← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Alcoholic Liver Disease

MONDO:0043693 Curated 2026-07-04T00:00:00Z 12 harmonized findings
falcon · 46 citations openai · 148 citations openscientist · 43 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Hepatic ethanol metabolism (via ADH/CYP2E1 to acetaldehyde) generates reactive oxygen species and reactive intermediates, producing oxidative stress, lipid peroxidation, and hepatocellular injury as the initiating events of ALD.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 90% generates toxic intermediates (acetaldehyde) and perturbs mitochondrial lipid oxidation, driving steatosis and hepatocyte stress
Falcon opens its causal chain with alcohol metabolism producing acetaldehyde and cellular stress driving steatosis.
DOI:10.1111/hepr.14206, DOI:10.1172/jci176345
openai CONCORDANT 95% Alcohol is metabolized to acetaldehyde via alcohol dehydrogenase and CYP2E1, which forms protein and DNA adducts. Increased CYP2E1 activity results in oxidative stress due to generation of ROS
OpenAI gives the detailed enzymatic mechanism (ADH/CYP2E1 → acetaldehyde, ROS, adducts, redox shift) as the initiating event.

ALD is a progressive spectrum advancing from hepatic steatosis to steatohepatitis/alcoholic hepatitis, then fibrosis, cirrhosis, and ultimately hepatocellular carcinoma.

UNANIMOUS INTEGRATED
pathophysiologyphenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 95% Alcohol-associated liver disease (ALD) is a spectrum of liver injury caused by chronic harmful alcohol exposure, ranging from **steatosis** to **steatohepatitis**, progressive **fibrosis**, **cirrhosis**, and **hepatocellular carcinoma (HCC)**
Falcon defines the full ALD spectrum from steatosis to HCC.
openai CONCORDANT 95% ALD progresses through a spectrum from **simple steatosis** to **alcoholic hepatitis** to **fibrosis/cirrhosis**, driven by escalating cellular damage and impaired repair mechanisms.
OpenAI describes the identical staged progression.

Alcohol disrupts the gut barrier, allowing translocation of bacterial LPS/PAMPs into the portal circulation, which (with hepatocyte DAMPs) activates Kupffer cells/macrophages via TLR signaling and drives pro-inflammatory cytokine production (the gut-liver axis).

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 90% increases portal influx of microbial PAMPs (e.g., LPS) and, together with hepatocyte DAMPs, triggers innate immune activation and systemic inflammation
Falcon describes gut barrier dysfunction driving innate immune activation.
openai CONCORDANT 90% Alcohol alters the gut microbiome and increases gut permeability resulting in translocation of bacterial products (e.g. LPS) into portal circulation, activation of macrophages and production of inflammatory cytokines
OpenAI gives the same gut-liver axis chain (permeability → LPS translocation → macrophage activation → cytokines).

Persistent injury activates hepatic stellate cells into collagen-producing myofibroblasts, driving extracellular matrix deposition and progression to fibrosis/cirrhosis.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Persistent injury promotes **hepatic stellate cell activation**, extracellular matrix deposition and fibrosis/cirrhosis, with risk of HCC
Falcon links stellate cell activation to ECM deposition and fibrosis.
openai CONCORDANT 90% Stellate cells transdifferentiate into myofibroblasts, producing extracellular matrix (collagen) in the space of Disse.
OpenAI adds the TGF-beta1-driven stellate-to-myofibroblast transition and collagen deposition in the space of Disse.

The PNPLA3 I148M variant is a major genetic risk modifier for ALD steatosis and progression to fibrosis/cirrhosis/HCC, with effects amplified by alcohol and coexisting obesity/metabolic dysfunction (a gene-environment interaction).

UNANIMOUS INTEGRATED
genetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Reported to increase liver fat and increase risk of fibrosis/cirrhosis/HCC, with stronger effects under obesity/T2D and alcohol exposure
Falcon reports PNPLA3 I148M as a risk modifier amplified by metabolic and alcohol exposures, alongside TM6SF2, MBOAT7, and protective HSD17B13.
openai CONCORDANT 90% The I148M variant of *PNPLA3* is a major genetic risk factor for ALD severity, promoting fat retention and fibrosis in the liver
OpenAI names PNPLA3 I148M as the major genetic risk factor and highlights the gene-environment interaction with alcohol and obesity.

Only a minority of heavy drinkers develop advanced ALD; roughly 8-20% progress to cirrhosis, and susceptibility is modulated by genetic, sex, and metabolic co-factors.

MAJORITY INTEGRATED
epidemiologyprognosis
ProviderStanceScoreEvidence
openai CONCORDANT 90% among heavy drinkers, ~90% develop fatty liver, roughly 10–35% may progress to alcoholic steatohepatitis, and about 8–20% to cirrhosis
OpenAI gives the full stage-by-stage progression fractions among heavy drinkers, including 8-20% cirrhosis.
falcon PARTIAL 50% AH has been described as occurring in ~4–8% of heavy drinkers in one recent review
Falcon reports overlapping progression figures (8-20% cirrhosis among fibrosis patients) but frames the alcoholic hepatitis fraction differently (~4-8% of heavy drinkers vs OpenAI's 10-35% steatohepatitis) using a different denominator — a quantitative discrepancy, not a contradiction.

Alcohol abstinence is the single most effective intervention and can halt or reverse early ALD across the disease spectrum.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 95% Alcohol abstinence is the most effective intervention to improve prognosis across ALD stages
Falcon names abstinence the most effective intervention across all stages.
openai CONCORDANT 90% Current expert consensus is that only **total alcohol abstinence** can reliably halt or reverse early ALD, highlighting the causal role of ethanol in the pathophysiology
OpenAI states only total abstinence reliably halts/reverses early ALD.

Corticosteroids are the principal (though limited-efficacy) pharmacologic therapy for severe alcoholic hepatitis, targeting its cytokine-driven inflammation.

MAJORITY LEAD
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 90% in one severe AH review, with limited efficacy and substantial non-response
Falcon describes corticosteroids as the only evidence-based pharmacologic treatment for severe AH, with limited efficacy and substantial non-response, and quantifies ~50-60% day-7 Lille response.
openai PARTIAL 50% has led to therapies like corticosteroids to dampen immune response
OpenAI mentions corticosteroids as an anti-inflammatory therapy rationale but does not detail their status as mainstay therapy, efficacy, or eligibility constraints.

Non-invasive tools stage ALD fibrosis and quantify alcohol exposure — elastography (VCTE/2D-SWE) and serum panels (ELF, Pro-C3, FIB-4) for fibrosis, and phosphatidylethanol (PEth) as an objective alcohol biomarker.

SINGLE LEAD
diagnosis
ProviderStanceScoreEvidence
falcon CONCORDANT 85% A recent biomarker review summarizes validated elastography thresholds and practical caveats
Falcon dedicates a diagnostics section to non-invasive fibrosis staging (elastography cutoffs, ELF, Pro-C3) and alcohol-exposure biomarkers (PEth).
openai SILENT —
OpenAI's pathophysiology-focused report does not cover diagnostic tests, fibrosis staging, or alcohol-exposure biomarkers.

Functional ADH1B and ALDH2 variants modify acetaldehyde exposure and may modify alcohol-related liver-disease susceptibility, particularly in East Asian populations.

MAJORITY LEAD
genetic_factor
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% ADH1B accelerates ethanol oxidation, whereas ALDH2 impairs acetaldehyde detoxification and increases oxidative stress, inflammation, and liver injury. Based on genotype combinations, individuals were stratified into five alcohol sensitivity groups with differing risks of cirrhosis and cancer
OpenScientist identifies functional alcohol-metabolism variants as a susceptibility lead and cites a source for the proposed risk stratification.
PMID:40943250
falcon PARTIAL 65% Population variation in **ALDH2** activity is highlighted in East Asian populations (30–40% with inactive ALDH2 polymorphisms), affecting acetaldehyde handling
Falcon supports the ALDH2 component and its population context, but does not make the full ADH1B/ALDH2 risk-stratification claim.
openai PARTIAL 65% **ALDH2 (Aldehyde Dehydrogenase 2)** – Mitochondrial enzyme that clears acetaldehyde. Deficiency (e.g. ALDH2*2 variant) causes acetaldehyde accumulation, exacerbating toxicity (e.g. flushing and liver damage).
OpenAI supports the alcohol-metabolism mechanism but does not provide the OpenScientist report's disease-risk stratification claim.

Fecal microbiota transplantation may improve short-term survival in severe alcohol-associated hepatitis, but requires further confirmation before integration as a disease treatment assertion.

SINGLE LEAD
treatment
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% showed a statistically significant increase in survival in the FMT arm at 28 days [RR 2.30 (1.24-4.28), P = 0.01] and 90 days [2.53 (1.34-4.77), P < 0.001]
OpenScientist reports a meta-analysis result, while also identifying the evidence as an area needing multicenter confirmation.
PMID:40359297
falcon SILENT —
Falcon does not address fecal microbiota transplantation.
openai SILENT —
OpenAI does not address fecal microbiota transplantation.

Pharmacologic treatment of alcohol-use disorder is important in ALD care; baclofen has randomized-trial evidence in cirrhosis, although the reported benefit is mixed and other drug-specific ALD evidence remains limited.

SINGLE LEAD
treatment
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Naltrexone and acamprosate reduce the relapse in the general AUD population, though data in ALD are limited. Baclofen is the only drug tested in randomized trials in cirrhosis, with early benefit but mixed results in later studies
OpenScientist reports a treatment lead with an explicit limitation on the evidence for ALD and mixed later baclofen results.
PMID:42476146, PMID:41258558, PMID:33326815
falcon SILENT —
Falcon discusses abstinence and severe-AH care but not AUD pharmacotherapy.
openai SILENT —
OpenAI does not address AUD pharmacotherapy.

Narrative

Overview

Both providers frame alcohol-associated liver disease (ALD) as a multifactorial, exposure-driven spectrum in which chronic harmful alcohol intake is the necessary trigger but host and metabolic co-factors determine who progresses. Falcon (Edison, comprehensive 15-section template) reads as a clinical-encyclopedic account spanning nomenclature (ALD within the 2023 steatotic-liver-disease framework), epidemiology, diagnostics, and treatment, whereas OpenAI (o3-deep-research, pathophysiology-focused template) reads as a deep mechanistic monograph on the molecular and cellular biology of injury. Despite the different templates, they converge on the same disease model: ethanol metabolism to acetaldehyde and ROS initiates hepatocellular injury, which — amplified by the gut-liver axis and fibrogenic wound healing — progresses from steatosis through alcoholic hepatitis to fibrosis, cirrhosis, and hepatocellular carcinoma.

Agreement

The reports are strongly concordant on the core pathophysiology. Both open the causal chain with hepatic ethanol metabolism (ADH/CYP2E1 to acetaldehyde) generating reactive oxygen species, oxidative stress, and hepatocellular injury. Both describe the gut-liver axis — increased intestinal permeability, LPS/PAMP translocation into the portal circulation, Kupffer-cell/macrophage activation, and pro-inflammatory cytokine output — as the inflammatory engine. Both identify hepatic stellate cell activation into collagen-producing myofibroblasts as the fibrogenic step, and both name PNPLA3 I148M as the dominant genetic risk modifier whose effect is amplified by alcohol and obesity. They agree on the full staged spectrum (steatosis to HCC), on the ~8-20% cirrhosis fraction among heavy drinkers, and on alcohol abstinence as the single most effective intervention.

Divergence

No direct contradictions were found; divergence is one of coverage and framing. Falcon uniquely supplies a diagnostics/biomarker layer (VCTE/2D-SWE elastography cutoffs, ELF and Pro-C3 serum panels, and phosphatidylethanol [PEth] as an objective alcohol-exposure biomarker), a population-epidemiology layer (GBD prevalence and rising U.S. mortality trends), a broader genetic panel (TM6SF2, MBOAT7, protective HSD17B13, ALDH2), and detailed severe-AH management (corticosteroid eligibility and Lille response, nutrition, early transplant, trial-stage agents). OpenAI instead goes deeper on molecular mechanism — CYP2E1-driven ROS, SREBP-1c/PPARalpha lipid dysregulation, regulated cell-death pathways (necroptosis, pyroptosis, ferroptosis), Mallory-Denk bodies, subcellular compartment injury, and the clinical phenotype of decompensated cirrhosis (ascites, varices, encephalopathy). The one quantitative discrepancy is the alcoholic-hepatitis progression fraction (Falcon ~4-8% of heavy drinkers vs OpenAI 10-35% steatohepatitis), which reflects different denominators rather than a genuine conflict.

Integration

The six unanimously concordant findings are strong promotion candidates for the disorder YAML: the ethanol-metabolism/oxidative-stress initiation node, the steatosis-to-HCC spectrum, the gut-liver-axis inflammation node, the stellate-cell fibrogenesis node, the PNPLA3 I148M genetic modifier, and abstinence as first-line treatment. These are cross-validated by both providers and align with the established ALD literature, so they can be curated as pathophysiology causal chains, a genetic_factor entry, and a treatment entry (each still requiring standard fetch-reference snippet verification before evidence blocks are attached).

Not integrated (leads)

Two findings are retained as leads rather than promoted. The corticosteroid severe-AH treatment claim is well supported by Falcon but only partially echoed by OpenAI, and its efficacy is limited and contested, so it should be curated only after confirming the eligibility/response evidence. The non-invasive diagnostics finding (elastography, PEth, serum fibrosis panels) rests on a single provider (Falcon; OpenAI is silent), so it needs corroboration and precise threshold sourcing before promotion. The single-provider molecular and epidemiology details (cell-death subtypes, SREBP-1c/PPARalpha, GBD/mortality statistics, secondary genetic modifiers) are likewise held as leads pending independent verification.

Cross-provider synthesis comparing falcon (Edison, comprehensive 15-section template), openai (o3-deep-research, pathophysiology-focused template), and openscientist (autonomous disease-characteristics template). Falcon and OpenAI are strongly concordant on core mechanism (ethanol metabolism/oxidative stress, gut-liver axis, stellate-cell fibrogenesis), the steatosis-to-HCC spectrum, PNPLA3 as the dominant genetic modifier, and abstinence as first-line treatment. No direct contradictions were found. Divergence is coverage/framing: falcon adds a diagnostics/biomarker layer (elastography, PEth) and population epidemiology (GBD/mortality trends) that OpenAI omits, while OpenAI provides deeper molecular detail (CYP2E1, SREBP-1c/PPARalpha lipid dysregulation, necroptosis/pyroptosis, Mallory-Denk bodies, cirrhosis-complication phenotypes). OpenScientist adds three explicitly retained leads: functional ADH1B/ALDH2 variants, fecal microbiota transplantation, and AUD pharmacotherapy. These were not promoted into the disease YAML in the Baijiu-mechanism PR because that PR is narrowly scoped and the claims still require deliberate, claim-level source verification. A minor quantitative discrepancy exists on the alcoholic-hepatitis progression fraction (falcon ~4-8% of heavy drinkers vs OpenAI 10-35% steatohepatitis, different denominators). best_matching_text values are verbatim excerpts; provider citations are representative and were not independently fetch-verified in this workspace artifact.